2021
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: embj2020106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2018
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
Tao Z, Muzumdar MD, Detappe A, Huang X, Xu ES, Yu Y, Mouhieddine TH, Song H, Jacks T, Ghoroghchian PP. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Letters 2018, 18: 2195-2208. PMID: 29533667, PMCID: PMC5957485, DOI: 10.1021/acs.nanolett.7b04043.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaHuman pancreatic ductal adenocarcinomaPancreatic tumorsMouse modelAutochthonous modelPoor overall prognosisAutochthonous mouse modelAutochthonous tumor modelTumor cell clustersOverall prognosisSurvival outcomesPancreatic cancerDuctal adenocarcinomaTransplanted tumorPreclinical studiesFree drug formulationDense stromaPreclinical testingTumor modelTumorsOxaliplatinNoninvasive optical imagingAnticancer agentsAnticancer drugsTherapeutic formulations
2017
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nature Communications 2017, 8: 1090. PMID: 29061961, PMCID: PMC5653666, DOI: 10.1038/s41467-017-00942-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzimidazolesCarcinoma, Pancreatic DuctalDNA Copy Number VariationsHumansImmunoblottingIndazolesMiceMorpholinesPancreatic NeoplasmsPhenylurea CompoundsPiperidinesProto-Oncogene MasProto-Oncogene Proteins p21(ras)PurinesPyrimidinesPyrimidinonesQuinazolinonesSulfonamidesThiazolesConceptsMitogen-activated protein kinasePDAC cellsCRISPR/Cas-mediated genome editingDependent mitogen-activated protein kinaseKRAS inhibitionGene expression profilesMetastasis-related genesProto-oncogene KRASGenome editingProtein kinasePI3K inhibitorsExpression profilesDeficient cellsPancreatic cancer cellsMechanisms of responsePDAC resistanceKRAS functionInduced sensitivityPancreatic ductal adenocarcinomaRole of KRASK inhibitorsCancer cellsKRAS inhibitorsAbsolute dependenceSubset of humans
2013
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. Clinical Cancer Research 2013, 19: 2310-2318. PMID: 23388504, PMCID: PMC4583193, DOI: 10.1158/1078-0432.ccr-12-2791.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaRational clinical trial designC-MetHGF/c-Met pathwayTyrosine kinase inhibitor sorafenibLimited survival benefitMajority of patientsCancer-related morbidityPathogenesis of HCCLatest clinical trialsKinase inhibitor sorafenibC-Met pathwayClinical trial designAdvanced diseaseLiver transplantationSurgical resectionSurvival benefitSystemic therapyLocal therapyTransarterial embolizationPreclinical dataClinical trialsInhibitor sorafenibTrial design